This is the largest reported series of periosteal osteosarcoma: 119 patients from 8 European tertiary centers collected over 28 years. It asks whether chemotherapy improves survival in this rare intermediate-grade bone tumor, where surgical excision has always been the cornerstone of treatment. Median age was 18 years; the femur and tibia together accounted for over 80% of cases.
When you see a diaphyseal surface lesion of the femur or tibia in a teenager with periosteal elevation on plain radiograph, think periosteal osteosarcoma before parosteal — the radiographic and histologic distinction matters because the prognosis and the debate around chemotherapy differ between these entities.
This paper is why achieving wide surgical margins takes priority over chemotherapy selection in periosteal osteosarcoma. Local recurrence multiplies mortality risk nearly ninefold, and no chemotherapy regimen. Two-drug, three-drug, or four-drug. Was shown to change that.
The chemotherapy question remains genuinely unresolved. This series is the largest ever published and still cannot prove benefit, partly because regimens varied widely and histologic response rates were poor (only 32% achieved >90% necrosis). Refer these patients to a specialist sarcoma center where the resection can be optimized.
A useful board distinction: periosteal osteosarcoma is intermediate grade with chondroblastic histology and a surface/subperiosteal origin. Parosteal is low grade, densely ossified, and arises on the bone surface. Getting this wrong changes management.
This is the largest reported series of periosteal osteosarcoma: 119 patients from 8 European tertiary centers collected over 28 years. It asks whether chemotherapy improves survival in this rare intermediate-grade bone tumor, where surgical excision has always been the cornerstone of treatment. Median age was 18 years; the femur and tibia together accounted for over 80% of cases.
When you see a diaphyseal surface lesion of the femur or tibia in a teenager with periosteal elevation on plain radiograph, think periosteal osteosarcoma before parosteal — the radiographic and histologic distinction matters because the prognosis and the debate around chemotherapy differ between these entities.
This paper is why achieving wide surgical margins takes priority over chemotherapy selection in periosteal osteosarcoma. Local recurrence multiplies mortality risk nearly ninefold, and no chemotherapy regimen. Two-drug, three-drug, or four-drug. Was shown to change that.
The chemotherapy question remains genuinely unresolved. This series is the largest ever published and still cannot prove benefit, partly because regimens varied widely and histologic response rates were poor (only 32% achieved >90% necrosis). Refer these patients to a specialist sarcoma center where the resection can be optimized.
A useful board distinction: periosteal osteosarcoma is intermediate grade with chondroblastic histology and a surface/subperiosteal origin. Parosteal is low grade, densely ossified, and arises on the bone surface. Getting this wrong changes management.